(RTTNews) - SpringWorks Therapeutics, Inc. (SWTX) Monday said its expects revenue for the fourth quarter from its only approved product Ogsiveo to be $61.5 million.
Ogsiveo net product revenues were $5.4 million in the fourth quarter of 2023, the first partial quarter of the U.S. launch.
For the full year, the company sees product revenue of $172 million.
The company also provided priorities and anticipated milestones in 2025 including:
Secure regulatory approval for Ogsiveo in the EU; Report initial data from the Phase 2 study evaluating Ogsiveo in patients with ovarian granulosa cell tumors in the first half of 2025; Secure FDA approval for mirdametinib in patients with NF1-associated plexiform neurofibromas or NF1-PN and launch. A decision from the regulator is expected on February 28, 2025; Obtain regulatory approval in the EU for mirdametinib for the treatment of NF1-PN and begin initial launch in 2025. The company also expects to report data from its early stage studies of drug candidates in 2025.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
